Xenon Pharmaceuticals INC

Xenon Pharmaceuticals Inc. held its annual meeting on June 2, 2026, where shareholders approved the 2026 Equity Incentive Plan and elected directors.

Xenon Pharmaceuticals announced positive Q1 2026 financial results, highlighting strong cash reserves and significant progress in its late-stage clinical trials for azetukalner.

Xenon Pharmaceuticals Inc. has amended its 2025 Inducement Equity Plan to increase the share reserve for new hires and rehires.

Xenon Pharmaceuticals Inc. announced the key dates and logistics for its 2026 annual meeting of shareholders, scheduled for June 2, 2026.

Xenon Pharmaceuticals Inc. announced the closing of an underwritten public offering, raising approximately $707.7 million in net proceeds through the sale of common shares and pre-funded warrants.

Xenon Pharmaceuticals Inc. filed a prospectus supplement to register $400 million in common shares for its at-the-market equity offering program.

Xenon Pharmaceuticals Inc. reported strong Q1 2026 results, with positive Phase 3 data for azetukalner in focal onset seizures and significant capital raised, positioning the company for future growth.

Xenon Pharmaceuticals Inc. reported a wider net loss in Q3 2025 as it significantly increased R&D spending to advance multiple late-stage clinical programs, including azetukalner for epilepsy and depression.

Xenon Pharmaceuticals Inc. reported a significantly wider net loss in Q2 2025 as research and development expenses surged for its late-stage clinical programs, despite a milestone payment from a collaboration.

Xenon Pharmaceuticals reports a net loss of $65.0 million for Q1 2025, with collaboration revenue of $7.5 million driven by a milestone payment from Neurocrine Biosciences.

Xenon Pharmaceuticals reported a net loss of $62.8 million for the third quarter of 2024, while advancing its clinical programs for azetukalner and other pipeline candidates.

Xenon Pharmaceuticals reports a net loss of $105.9 million for the first six months of 2024, while advancing its clinical programs and early-stage pipeline.

Xenon Pharmaceuticals Inc. continues to advance its late-stage clinical pipeline, including azetukalner for epilepsy and depression, while reporting increased net losses and R&D expenses for fiscal year 2025.

Xenon Pharmaceuticals' 10-K filing details the company's financial results for 2024 and provides updates on its pipeline, particularly the progress of azetukalner in epilepsy and neuropsychiatric disorders.

Xenon Pharmaceuticals' 10-K filing outlines the details of its common and preferred shares, along with corporate governance and regulatory compliance.

Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals to cover tax obligations related to RSU vesting.

Xenon Pharmaceuticals Director Gillian Cannon sold 1,190 common shares to cover tax obligations related to RSU vesting.

Director Gary Patou exercised restricted share units and received new equity grants in Xenon Pharmaceuticals.

Director Patrick Machado acquired common shares through RSU vesting and received new equity grants.

Director Justin D. Gover reported the vesting of restricted share units and the acquisition of new equity awards.

Director Elizabeth A. Garofalo acquired common shares through RSU vesting and received new equity grants.

Xenon Pharmaceuticals Inc. has announced its annual meeting of shareholders will be held virtually on June 2, 2026, to vote on key corporate matters including director elections and equity incentive plans.

Xenon Pharmaceuticals will hold its annual shareholder meeting virtually on June 4, 2025, to discuss financial statements, elect directors, approve executive compensation, and appoint auditors.

Xenon Pharmaceuticals will hold its annual shareholder meeting virtually on June 4, 2025, to discuss financial statements, elect directors, and vote on executive compensation and auditor appointment.

Xenon Pharmaceuticals is asking shareholders to approve amendments to its 2014 Equity Incentive Plan, including increasing the number of issuable shares by 5,200,000, at the upcoming annual meeting.

Janus Henderson Group plc has reported beneficial ownership of 4,175,982 common shares, representing 4.5% of the class, in Xenon Pharmaceuticals Inc.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported beneficial ownership of 6.26% of Xenon Pharmaceuticals, Inc. common shares as of March 31, 2026.

Driehaus Capital Management LLC has increased its beneficial ownership of Xenon Pharmaceuticals Inc. common stock to 4.87%, acquiring 4,491,653 shares.

Wellington Management Group and its affiliates have reported a 6.2% beneficial ownership stake in Xenon Pharmaceuticals Inc. as of December 31, 2025.

Janus Henderson Group plc has reported a 5.1% beneficial ownership stake in XENON PHARMACEUTICALS INC. common stock.

Wellington Management Group and its affiliates have disclosed a 2.8% passive ownership stake in Xenon Pharmaceuticals Inc. as of June 30, 2025.